DUET remains at nose-bleed levels

James Dunphy

Investors need to discard history and believe in several improbabilities to buy DUET at current levels. Most importantly, investors need to believe the oxygen supply from DUET’s promised distributions will deny the forces of fundamental valuation’s gravity. Dividends can be solid indicators of company health, but equally can mask chronic... Show More

Join the conversation

No comments.